Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study.

Michielsen, P;Bottieau, E;Van Vlierberghe, H;Van Marck, E;Horsmans, Yves;et.al.
(2009) Acta Gastro-Enterologica Belgica — Vol. 72, n° 4, p. 389-393 (2020)

Files

238752.pdf
  • Restricted Access
  • Adobe PDF
  • 3.34 MB

Details

Authors
  • Michielsen, P
    Author
  • Bottieau, E
    Author
  • Van Vlierberghe, H
    Author
  • Van Marck, E
    Author
  • Collaborator
Show more
Abstract
In Belgium, 10-15% of patients infected with the human immunodeficiency virus (HIV) are coinfected with hepatitis C virus (HCV). Because of increased incidence of antiretroviral drug-related hepatotoxicity and more rapid clinical evolution towards end-stage liver disease, treatment of chronic hepatitis C becomes a priority. We report the results of a multi-centred Belgian study evaluating efficacy and safety of peginterferon alpha-2b plus ribavirin in HIV-HCV co-infected patients without AIDS and without decompensated liver disease. Forty-one patients, all genotypes, were screened to participate. Eventually 37 received treatment with peginterferon alpha-2b (1.5 microg/kg/week) plus daily weight-based ribavirin for 52 weeks. About one third of the patients were genotypes 1, 2/3, and genotype 4, most of the latter being of Central African origin. About 56% of the patients had severe fibrosis (Metavir score > or = F3). Sustained viral response (SVR) at 24 weeks of follow-up was observed in 10/37 (27%) of patients. SVR was higher in genotype 2/3 compared to genotype 1/4 (46.7% versus 13.6%; p = 0.06) and in low (F0-F1) versus high (F2-F4) grade fibrosis (p = 0.06). Treatment was withdrawn for side effects in 11/37 patients (30%). One Child A cirrhosis patient at the start of therapy died 7 months after treatment withdrawal as a result of severe haemolytic anaemia. It can be concluded that weight-based peginterferon alpha-2b plus ribavirin can be successful in selected HIV-HCV co-infected patients. Caution should be applied in patients with advanced liver disease.
Affiliations

Citations

Michielsen, P., Bottieau, E., Van Vlierberghe, H., Van Marck, E., Vandemaele, E., Denys, M., Brasseur, J. P., & Popan, M. (2009). Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study. Acta Gastro-Enterologica Belgica, 72(4), 389-393. https://hdl.handle.net/2078.5/168581 (Original work published 2020)